Synthetic cannabinoid use among a sample of individuals enrolled in community-based recovery programs: Are synthetic cannabinoids actually preferred to other drugs?

References

• Baumann M H, Volkow N D. Abuse of new psychoactive substances: Threats and solutions. Neuropsychopharmacol. 2016;41:63.
   Google Scholar
• Perrone, D. Designer drugs. In Brownstein HH, ed. The Handbook of Drugs and Society. Chichester, UK: Wiley Blackwell, 2016; 149–175.
   Google Scholar
• Measham, F. Social issues in the use of novel psychoactive substances: Differentiated demand and ideological supply. In Dargan PI, Wood DM, eds. Novel Psychoactive Substances: Differentiated Demand and Ideological Supply. London, UK: Elsevier; 2013;105–127.
   Google Scholar
• Smith KE, Bunting AM, Staton M, et al. Examination of synthetic cannabinoid and cathinone use among a drug-using offender sample, 2013–2015. J Psychoactive Drugs. 2017;49:436–445.
   PubMed Web of Science ®Google Scholar
• Wagner JA, Hu K, Karcher J, et al. CB1 cannabinoid receptor antagonism promotes remodeling and cannabinoid treatment prevents endothelial dysfunction and hypotension in rats with myocardial infarction. Brit J Pharmacol. 2013;138:1251–1258.
   Google Scholar
• Burrows BT, Watterson, LR, Egnatios J, Olive, MF. Synthetic cannabinoids: a summary of selected phenomena with respect to behavioral pharmacology and abuse liability. Handb Cannabis Rel Pathol. 2017;691–699.
   Google Scholar
• Van Hout, MC, Hearne E. User experiences of development of dependence on the synthetic cannabinoids, 5f-AKB48 and 5F-PB-22, and subsequent withdrawal syndromes. Int J Ment Health Ad. 2017;5:565–579.
   Web of Science ®Google Scholar
• Atwood BK, Huffman J, Straiker A, & Mackie K. JWH018, a common constituent of ‘Spice’ herbal blends, is a potent and efficacious cannabinoid CB1 receptor agonist. Brit J Pharmacol. 2010;160:585–593.
   PubMed Web of Science ®Google Scholar
• Le Boisselier R, Alexandre J, Lelong‐Boulouard V, Debruyne D. Focus on cannabinoids and synthetic cannabinoids. Clin Pharmacol Ther. 2017;101: 220–229.
   PubMed Web of Science ®Google Scholar
• Castaneto MS, Gorelick DA, Desrosiers NA, et al. Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Dependen. 2014;144:12–41.
   PubMed Web of Science ®Google Scholar
• Cohen K, Kapitány-Fövény M, Mama Y, et al. The effects of synthetic cannabinoids on executive function. Psychopharmacol. 2017;234:1121–1134.
   PubMed Web of Science ®Google Scholar
• Gunderson EW, Haughey, HM, Ait‐Daoud N, Joshi AS, Hart CL. “Spice” and “K2” herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. Am J Addict. 2012;21:320–326.
   PubMed Web of Science ®Google Scholar
• Kevin RC, Wood KE, Stuart J, Mitchell AJ, et al. Acute and residual effects in adolescent rats resulting from exposure to the novel synthetic cannabinoids AB-PINACA and AB-FUBINACA. J Psychopharmacol. 2017;31:757–769.
   PubMed Web of Science ®Google Scholar
• Papanti D, Schifano F, Botteon G. “Spiceophrenia”: A systematic overview of “Spice”‐related psychopathological issues and a case report. Hum Psychopharmacol. 2013;28:379–389.
   PubMed Web of Science ®Google Scholar
• Seely KA, Lapoint J, Moran JH, Fattore L. Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry. 2012;39:234–243.
   PubMed Web of Science ®Google Scholar
• Spaderna M, Addy PH, D’Souza DC. Spicing things up: Synthetic cannabinoids. Psychopharmacol. 2013;228:525–540.
   PubMed Web of Science ®Google Scholar
• Tait RJ, Caldicott D, Mountain D, Hill SL, Lenton S. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol. 2016;54:1–13.
   PubMed Web of Science ®Google Scholar
• Baker S. An Examination of the Reasons that Prisoners Use Spice (Synthetic Cannabinoids). University of Cambridge [Master’s Thesis]. Cambridge, UK: Cambridge University; 2015.
   Google Scholar
• Bonar EE, Ashrafioun L, Ilgen MA. Synthetic cannabinoid use among patients in residential substance use disorder treatment: prevalence, motives, and correlates. Drug Alcohol Depen. 2014;143:268–271.
   PubMed Web of Science ®Google Scholar
• Fattore L, Fratta W. Beyond THC: the new generation of cannabinoid designer drugs. Front Behav Neurosci. 2011;5:60.
   PubMed Web of Science ®Google Scholar
• Ninnemann AL, Lechner WV, Borges A, Lejuez CW. Synthetic cannabinoids to avoid urine drug screens: Implications for contingency management and other treatments for drug dependence. Addict Behav. 2016;63:72–73.
   PubMed Web of Science ®Google Scholar
• Perrone D, Helgesen RD, Fischer RG. United States drug prohibition and legal highs: How drug testing may lead cannabis users to Spice. Drugs-Edu PrevPolic. 2013;20:216–224.
   Web of Science ®Google Scholar
• Ralphs R, Williams L, Askew R, Norton A. Adding spice to the porridge: The development of a synthetic cannabinoid market in an English prison. Int J Drug Policy. 2017;40:57–69.
   PubMed Web of Science ®Google Scholar
• Walker DF. The informal economy in prison: Studying prisoner trading can offer significant insights into prison life observes Dulcie Faure Walker. Crim Just Matters. 2015;99:18–19.
   Google Scholar
• Ninnemann A, MacPherson L. Query and test for synthetic cannabinoids in drug treatment and research. Int J Drug Policy. 2015;26:531–532.
   PubMed Web of Science ®Google Scholar
• Vandrey R, Dunn KE, Fry JA, Girling ER. A survey study to characterize use of Spice products (synthetic cannabinoids). Drug Alcohol Dependen. 2012;120:238–241.
   PubMed Web of Science ®Google Scholar
• Winstock AR, Barratt M. Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug Alcohol Dependen. 2013;131:106–111.
   PubMed Web of Science ®Google Scholar
• Wood DM, Measham F, Dargan PI. ‘Our favourite drug’: prevalence of use and preference for mephedrone in the London night-time economy 1 year after control. J Subst Use. 2012;17:91–97.
   Web of Science ®Google Scholar
• Soussan C, Kjellgren A. The users of Novel Psychoactive Substances: Online survey about their characteristics, attitudes and motivations. Int J Drug Policy. 2016;32:77–84.
   PubMed Web of Science ®Google Scholar
• Barnard M, Russell C, McKeganey N, Hamilton-Barclay T. The highs and lows of NPS/“Legal High” use: Qualitative views from a UK online survey. Drug-Educ, Prev Polic. 2017;24:96–102.
   Web of Science ®Google Scholar
• Dines A. M., Wood, D. M., Yates, C, et al. Acute recreational drug and new psychoactive substance toxicity in Europe: 12 months data collection from the European Drug Emergencies Network (Euro-DEN). Clin Toxicol. 2015;53:893–900.
   PubMed Web of Science ®Google Scholar
• Jaenicke NJ, Pogoda W, Paulke A, Wunder C, Toennes SW. Retrospective analysis of synthetic cannabinoids in serum samples–epidemiology and consumption patterns. Forensic Sci Int. 2014;242:81–87.
   PubMed Web of Science ®Google Scholar
• Barratt MJ, Cakic V, Lenton S. Patterns of synthetic cannabinoid use in Australia. Drug Alcohol Rev. 2013;32:141–146.
   PubMed Web of Science ®Google Scholar
• Blackman S, Bradley R. From niche to stigma—Headshops to prison: Exploring the rise and fall of synthetic cannabinoid use among young adults. Int J Drug Policy. 2017;40:70–77.
   PubMed Web of Science ®Google Scholar
• McElrath K, Van Hout MC. A preference for mephedrone: Drug markets, drugs of choice, and the emerging “legal high” scene. J Drug Issues. 2011;41:487–507.
   Web of Science ®Google Scholar
• Sutherland R, Bruno R, Peacock A, et al. Motivations for new psychoactive substance use among regular psychostimulant users in Australia. Int J Drug Policy. 2017;43:23–32.
   PubMed Web of Science ®Google Scholar
• Caviness CM, Tzilos G, Anderson BJ, Stein MD. Synthetic cannabinoids: Use and predictors in a community sample of young adults. Subst Abus. 2015;36:368–373.
   PubMed Web of Science ®Google Scholar
• Joseph AM, Manseau MW, Lalane M, Rajparia A, Lewis CF. Characteristics associated with synthetic cannabinoid use among patients treated in a public psychiatric emergency setting. Am J Drug Alcohol Ab. 2017;43:117–122.
   PubMed Web of Science ®Google Scholar
• Richardson JB, Vil CS., Wish E, Cooper C. “On papers”: Perceptions of synthetic cannabinoid use among black males under criminal justice supervision. Health Justice. 2016;4:1.
   Google Scholar
• Sutherland R, Peacock A, Whittaker E, et al. New psychoactive substance use among regular psychostimulant users in Australia, 2010–2015. Drug Alcohol Dependen. 2016;161:110–118.
   PubMed Web of Science ®Google Scholar
• Martinotti G, Lupi M., Acciavatti T, et al. Novel psychoactive substances in young adults with and without psychiatric comorbidities. Biomed Res Int. 2014;2014.
   Web of Science ®Google Scholar
• Bassir Nia A, Medrano B, Perkel C, Galynker I, Hurd YL. Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis. J Psychopharmacol. 2016;30:1321–1330.
   PubMed Web of Science ®Google Scholar
• Davey Z, Schifano F, Corazza O, Deluca P, Psychonaut Web Mapping Group. e-Psychonauts: conducting research in online drug forum communities. J Ment Health. 2012;21:386–394.
   PubMed Web of Science ®Google Scholar
• Deluca P, Davey Z, Corazza O, et al. Identifying emerging trends in recreational drug use: Outcomes from the Psychonaut Web Mapping Project. Progress Neuro-Psychoph. 2012;39:221–226.
   PubMed Web of Science ®Google Scholar
• Schifano F, Ricciardi A, Corazza O, et al. New drugs of abuse on the Web: the role of the Psychonaut Web Mapping Project. Rivista di Psichiatria. 2010;45:88–93.
   PubMed Web of Science ®Google Scholar
• Doremus-Fitzwater TL, Varlinskaya EI, Spear LP. Motivational systems in adolescence: Possible implications for age differences in substance abuse and other risk-taking behaviors. Brain Cognition. 2010;72:114–123.
   PubMed Web of Science ®Google Scholar
• Vohs KD, Baumeister RF. (Eds.). Handbook of self-regulation: research, theory, and applications. New York, NY: Guilford Publications. 2016.
   Google Scholar
• Anthony JC, Petronis KR. Early-onset drug use and risk of later drug problems. Drug Alcohol Dependen. 1995;40:9–15.
   PubMed Web of Science ®Google Scholar
• McGue M, Iacono WG, Legrand LN, Malone S, & Elkins I. Origins and consequences of age at first drink. I. Associations with substance‐use disorders, disinhibitory behavior and psychopathology, and P3 amplitude. Alcohol Clin Exp Res. 2001;25:1156–1165.
   PubMed Web of Science ®Google Scholar
• Miller BL, Stogner JM, Miller JM, Fernandez, MI. The arrest and synthetic novel psychoactive drug relationship: observations from a young adult population. J Drug Issues. 2017;47:91–103.
   Web of Science ®Google Scholar
• Wish ED, Artigiani EE, Billing AS. Community Drug Early Warning System: The CDEWS Pilot Project. Washington, DC: Office of National Drug Control Policy. Executive Office of the President; 2013.
   Google Scholar
• Gunderson EW, Haughey HM, Ait-Daoud N, Joshi AS, Hart C. A survey of synthetic cannabinoid consumption by current cannabis users. Subst Abus. 2014;35:184–189.
   PubMed Web of Science ®Google Scholar
• Office of National Drug Control Policy. Community drug early warning system: the CDEWS-2 Replication Study. Washington, DC. 2015.
   Google Scholar
• Ginsburg BC, McMahon LR, Sanchez JJ, Javors MA. Purity of synthetic cannabinoids sold online for recreational use. J Anal Toxicol. 2012;36:66–68.
   PubMed Web of Science ®Google Scholar
• van Amsterdam JG, Nabben T, Keiman D, Haanschoten G, Korf D. Exploring the attractiveness of New Psychoactive Substances (NPS) among experienced drug users. J Psychoactive Drugs. 2015;47:177–181.
   PubMed Web of Science ®Google Scholar
• Ritter A. Commentaries on Wilkins. Addiction. 2014;109:1587–1588.
   PubMed Web of Science ®Google Scholar
• Lauritsen KJ, Rosenberg H. Comparison of outcome expectancies for synthetic cannabinoids and botanical marijuana. Am J of Drug Alc Abus. 2016;42:377–384.
   PubMed Web of Science ®Google Scholar
• Cairns R, Brown JA, Gunja, N, Buckley NA. The impact of Australian legislative changes on synthetic cannabinoid exposures reported to the New South Wales Poisons Information Centre. Int J Drug Pol. 2017;4:74–82.
   Google Scholar
• Rickart AJ, Parmar JD, Crank ST. Interpersonal violence and synthetic cannabinoids. Brit J Oral Max Surg. 2017;55:336.
   PubMed Web of Science ®Google Scholar
• van Amsterdam J, Brunt T, van den Brink W. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. J Psychopharmacol. 2015;29:254–263.
   PubMed Web of Science ®Google Scholar
• Waugh J, Najafi J, Hawkins L, et al. Epidemiology and clinical features of toxicity following recreational use of synthetic cannabinoid receptor agonists: a report from the United Kingdom National Poisons Information Service. Clin Toxicol. 2016;54:512–518.
   PubMed Web of Science ®Google Scholar
• Pirona A, Bo A, Hedrich D, et al. New psychoactive substances: Current health-related practices and challenges in responding to use and harms in Europe. Int J Drug Policy. 2017;40:84–92.
   PubMed Web of Science ®Google Scholar
• Labay LM, Caruso JL, Gilson, TP, et al. Synthetic cannabinoid drug use as a cause or contributory cause of death. Forensic Sci Int. 2016;260:31–39.
   PubMed Web of Science ®Google Scholar
• Bassir Nia A, Spriggs S, Perkel C, et al. Synthetic cannabinoid use in relation to psychosis: Evaluation of the role of stress and immune systems. Biol Psychiat. 2017;81:S232.
   Web of Science ®Google Scholar
• Davidson C, Opacka-Juffry J, Arevalo-Martin A, et al. Spicing up pharmacology: A review of synthetic cannabinoids from structure to adverse events. Advances Pharmacol. 2017;80:135–168.
   PubMedGoogle Scholar
• Every-Palmer S. Synthetic cannabinoid JWH-018 and psychosis: an explorative study. Drug Alcohol Dependen. 2011;117:152–157.
   PubMed Web of Science ®Google Scholar
• Darke S. Self-report among injecting drug users: A review. Drug Alcohol Dependen. 1998;3:253–263.
   Google Scholar
• Denis C, Fatséas M, Beltran V, et al. Validity of the self-reported drug use section of the Addiction Severity Index and associated factors used under naturalistic conditions. Subst Use Misuse. 2012;47:356–363.
   PubMed Web of Science ®Google Scholar
• Zanis DA, McLellan, AT, Randall M. Can you trust patient self-reports of drug use during treatment? Drug Alcohol Dependen. 1994;35:127–132.
   PubMed Web of Science ®Google Scholar
• Frinculescu A, Lyall CL, Ramsey J, Miserez B. Variation in commercial smoking mixtures containing third‐generation synthetic cannabinoids. Drug Test Anal. 2017;9:327–333.
   PubMed Web of Science ®Google Scholar
• Weinstein AM, Rosca P, Fattore L, London ED. Synthetic cathinone and cannabinoid designer drugs pose a major risk for public health. Front Psychiatry. 2017;8:156.
   PubMed Web of Science ®Google Scholar
• Hervás ES. Synthetic cannabinoids: characteristics, use and clinical implications. Arch Psych Psychother. 2017;19:42–48.
   Web of Science ®Google Scholar